Result:Steady· Market: Down#Turnaround#Base effect
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 4.12 | 42.6% | 38.1% |
| Total Income | 4.17 | 42.8% | 37.8% |
| Expenditure | 5.96 | 31.1% | 57.1% |
| PBT | 2.41 | 265.8% | 133.7% |
| Net Profit | 1.87 | 272.5% | 135.2% |
| OPM | 83.85% | 89.81pp | 165.03pp |
| NPM | 44.88% | 59.78pp | 124.17pp |
| EPS | 0.63 | 23.5% | 55.3% |
Pharma core metric (revenue) fell 38.2% YoY even as the company swung from a large loss to a small profit against a deeply depressed prior-year base, capping quality despite the turnaround.
Informational and educational content only. Not investment advice.